Most Read Articles
Stephen Padilla, 2 days ago
Treatment with oral thrombopoietin receptor agonist eltrombopag leads to similar platelet counts in patients with chronic immune thrombocytopaenia (cITP) and persistent (per)ITP, according to the results of phase III (EXTEND) and IV studies presented at the 23rd Congress of the European Hematology Association (EHA 2018) held in Stockholm, Sweden.
Pearl Toh, 4 days ago
Lonely people were twice as likely to die from any cause than people who did not feel lonely, according to a study based on a national survey presented at the recent EuroHeartCare 2018 in Dublin, Ireland. Also, loneliness is associated with poorer patient-reported outcomes in terms of mental and physical health in patients with heart disease.
15 Jun 2018
Higher activity of plasma xanthine oxidase appears to be linked to insulin resistance and liver dysfunction among type 2 diabetes mellitus (T2DM) patients with metabolic syndrome (MetS), according to a recent Japan study.
Jairia Dela Cruz, 2 days ago
A treatment regimen combining daratumumab plus bortezomib, melphalan and prednisone markedly extends progression-free survival in patients with multiple myeloma, inducing deep responses and demonstrating acceptable tolerability regardless of baseline renal function, according to the results of the phase III ALCYONE study.

Common soap additive linked to colonic inflammation

Pank Jit Sin
12 Jun 2018

The common antimicrobial agent, triclosan, has been implicated in colonic inflammation and the disease development of colitis and colitis-associated colon cancer, reveals a study appearing in Science Translational Medicine. [doi:10.1126/scitranslmed.aan4116]

While the study was done in mice, the research team, led by senior author Guodang Zhang of the University of Massachusetts Amherst, US, reported in Science Translational Medicine that “the results, for the first time, suggest that triclosan could have adverse effects on gut heath.” In the study, the researchers looked at the effects of triclosan on colonic inflammation and colon cancer using a variety of mouse models. Zhang noted that triclosan promoted colonic inflammation and colonic tumorigenesis in all the models tested.

Coauthor and food scientist Hang Xiao, added, "In particular, we used a genetically engineered mouse model which develops spontaneous inflammatory bowel disease or IBD. Also, treatment with triclosan significantly increased disease development of IBD in the mice, suggesting that IBD patients may need to reduce exposure to this compound."

In order to elucidate the mechanisms behind the development of IBD and tumorigenesis, the research team found that gut microbiota is critical for the observed adverse effects of triclosan. Feeding triclosan to mice reduced the diversity and changed the composition of the gut microbiome, a result similar to what was observed in a human study conducted by others, said Zhang. Also, triclosan had no effect in a germ-free mouse model where there is no gut microbiome present, nor in a genetically engineered mouse model where there is no Toll-like receptor 4 (TLR4) – an important mediator for host-microbiota communications. "This is strong evidence that gut microbiota is required for the biological effects of triclosan" Zhang points out.

According to coauthors Haixia Yang and Weicang Wang, triclosan is one of the most widely used antimicrobial ingredients and found in more than 2,000 consumer products. It was also revealed that the National Health and Nutrition Examination Survey reported that 75 percent of all urine samples tested in the US showed traces of triclosan. It is among the top ten most common chemicals found in US rivers. [Available at https://www.cdc.gov/biomonitoring/Triclosan_FactSheet.html]

Yang, who is a postdoctoral fellow in the Zhang Laboratory, said: “Because this compound is so widely used, our study suggests that there is an urgent need to further evaluate the impact of triclosan exposure on gut health in preparation for the potential establishment of further regulatory policies.”

Ed: Triclosan is of particular interest to healthcare professionals as it is an ingredient often used as a marketing gimmick in skincare and cleaning products. It is also found in a wide range of hospital disinfectants. In September 2016, the US Food and Drug Administration issued a ruling that over-the-counter consumer antiseptic products containing certain active ingredients can no longer be marketed. In particular, two ingredients were named—triclosan and triclocarban. The ruling was founded on the fear of microbial resistance and hormonal interference, plus the lack of evidence suggesting that the active ingredients were better than simple soap and water in preventing illness and the spread of infections. [https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm517478.htm]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 2 days ago
Treatment with oral thrombopoietin receptor agonist eltrombopag leads to similar platelet counts in patients with chronic immune thrombocytopaenia (cITP) and persistent (per)ITP, according to the results of phase III (EXTEND) and IV studies presented at the 23rd Congress of the European Hematology Association (EHA 2018) held in Stockholm, Sweden.
Pearl Toh, 4 days ago
Lonely people were twice as likely to die from any cause than people who did not feel lonely, according to a study based on a national survey presented at the recent EuroHeartCare 2018 in Dublin, Ireland. Also, loneliness is associated with poorer patient-reported outcomes in terms of mental and physical health in patients with heart disease.
15 Jun 2018
Higher activity of plasma xanthine oxidase appears to be linked to insulin resistance and liver dysfunction among type 2 diabetes mellitus (T2DM) patients with metabolic syndrome (MetS), according to a recent Japan study.
Jairia Dela Cruz, 2 days ago
A treatment regimen combining daratumumab plus bortezomib, melphalan and prednisone markedly extends progression-free survival in patients with multiple myeloma, inducing deep responses and demonstrating acceptable tolerability regardless of baseline renal function, according to the results of the phase III ALCYONE study.